Safe Management of People With Type 1 Diabetes and EAting Disorders studY
STEADY-II
1 other identifier
interventional
40
1 country
1
Brief Summary
There is currently no effective intervention for type 1 diabetes and eating disorders. The main objective of STEADY Stage 2 is to test the feasibility of the newly developed STEADY intervention. STEADY was co-designed by using Experience Based Co-Design methodology and other qualitative methods (focus groups, interviews). These findings informed the development of a T1DM cognitive behaviour therapy (CBT) manual. The intervention will now be tested in a feasibility Randomised Controlled Trial (RCT) in adults with type 1 diabetes and eating disorders and compared with usual clinical care. If STEADY is feasible, this may provide an effective intervention for this population. This study will take place at King's College London. Participants will remain in the study for 6 months, with a 12-month extended observation period. The study is expected to end in February 2023.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 9, 2021
CompletedFirst Posted
Study publicly available on registry
December 1, 2021
CompletedStudy Start
First participant enrolled
January 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 29, 2024
CompletedMarch 5, 2024
March 1, 2024
2.1 years
November 9, 2021
March 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
HbA1c
HbA1c measured in mmol/mol
6 months
Study Arms (2)
STEADY intervention group
EXPERIMENTALTreatment as usual group (control)
NO INTERVENTIONInterventions
STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
Eligibility Criteria
You may qualify if:
- Adults (≥18 years);
- Diagnosis of type 1 diabetes mellitus for at least 6 months;
- Current disordered eating: defined as fear of insulin as weight gaining, avoidance/ restriction of insulin to control weight, food restriction, binge eating, any additional disordered eating behaviour as described by the 5th revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), or 11th Revision of the International Classification of Diseases (ICD-11); AND/OR score of 15 on EDE-QS, AND/OR a score of 20 on the DEPS-R.
- Prepared to take part in a cognitive-behavioural therapy approach behaviour change strategy plus diabetes education intervention (with up to 12 sessions) with a varying proportion of face-to-face and virtual delivery mode;
- Prepared to take part in the control group - treatment as usual (TAU)
- Prepared to attend physical and mental health check-up at baseline and at the end of the intervention (control arm and intervention arm) face-to-face;
- Currently under the care of a diabetes specialist team (as this study does not replace usual diabetes care);
- Confirms availability to attend all sessions as part of the intervention (with the option of rescheduling sessions when necessary. Therapy sessions may be in person or via videoconference);
- Investigator has confidence that the participant is able to fulfill all of the trial protocol requirements;
- Participant has capacity to consent to the study. This is assessed by ability to explain information about their involvement in the study.
You may not qualify if:
- HbA1c \>15%/ 140.4 mmol/mol;
- More than 2 admissions for DKA in the past 12 months;
- More than 2 SH episodes (defined as needing 3rd party assistance) in the past 12 months due to insulin omission (not if triggered by infection or canula failure);
- Severe mental illness, including severe depression with suicidal ideation, psychosis, emotionally unstable personality disorder requiring more intensive psychiatric treatment, substance problem use and dependence. (Potential participants with more severe mental illness are unlikely to benefit from a CBT based approach, therefore will be excluded to not delay their treatment. Investigators will use their clinical judgement, in agreement with the trial team. Mental health assessment by a psychiatrist is part of the baseline visit.);
- Body mass index below 15kg/m2 or above 40kg/m2;
- Significant cognitive impairment, e.g. dementia, learning disability;
- Unable to speak/hear/understand/read/write in English;
- Unable to give written informed consent;
- Pregnant or planning pregnancy;
- Advanced diabetes complications (end stage renal failure, registered blind, limb amputation);
- Uncontrollable electrolyte disturbance, low blood pressure (\<100/60mmHg), ECG abnormalities related to malnutrition (QTc-prolongation) or other physical conditions requiring inpatient treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King's College Hospital
London, United Kingdom
Related Publications (1)
Stadler M, Zaremba N, Harrison A, Brown J, Pillay D, Allan J, Tan R, Ayis S, Konstantara E, Treasure J, Hopkins D, Ismail K. Safety of a co-designed cognitive behavioural therapy intervention for people with type 1 diabetes and eating disorders (STEADY): a feasibility randomised controlled trial. Lancet Reg Health Eur. 2025 Jan 20;50:101205. doi: 10.1016/j.lanepe.2024.101205. eCollection 2025 Mar.
PMID: 39902232DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 9, 2021
First Posted
December 1, 2021
Study Start
January 18, 2022
Primary Completion
February 29, 2024
Study Completion
February 29, 2024
Last Updated
March 5, 2024
Record last verified: 2024-03